Corbus Pharmaceuticals Holdings
CRBP
Positions held
Your positionsCRBP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $101.93M | Enterprise value | -$11.75M | Trailing P/E | — | Forward P/E | -0.96 |
| PEG | — | Price / book | 0.96 | Beta | 2.63 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -95.6% | ROA | -53.0% | Debt / equity | 0.04 |
| Current ratio | 5.71 | Free cash flow | -$49.62M | Analyst recommendation | strong_buy | Mean target | $34.03 |
| 52w high | $20.56 | 52w low | $5.13 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$35.0M | -$23.0M | -$20.6M | -$23.3M | -$17.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$36.2M | -$24.3M | -$22.0M | -$24.4M | -$19.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$42.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$34.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-17 · Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
2026-09-15 · Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
2026-09-14 · Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
2026-08-17 · Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13 · Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating
2026-08-07 · Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating
2026-08-06 · Corbus Pharmaceuticals: Q2 Earnings Snapshot
2026-08-06 · Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
2026-08-04 · Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Price (daily)
Full chart · RSI · MACD · patterns